Merck Serono pipeline Audited

Neurodegenerative diseases

ONO-4641 (oral S1P receptor modulator)

Multiple Sklerose

Phase II

ATX-MS-1467 (immune tolerazing agent)

Multiple Sklerose

Phase I

PI-2301 (second generation peptide copolymer)

Multiple Sklerose

Phase I

Oncology

Erbitux® (cetuximab, anti-EGFR mAb)

Head and neck cancer

Filed in China

Cilengitide (integrin inhibitor)

Glioblastoma

Phase III

Cilengitide (integrin inhibitor)

Non-small cell lung cancer

Phase II

L-BLP25 (MUC1-antigen-specific cancer 
immunotherapy)

Non-small cell lung cancer

Phase III
(in Asia)

TH-302 (hypoxia targeted alkylating drug)

Soft tissue sarcoma

Phase III

TH-302 (hypoxia targeted alkylating drug)

Pancreatic cancer

Phase III

TH-302 (hypoxia targeted alkylating drug)

Hematological malignancies and
combination trials in solid tumors

Phase I

DI17E6 (Anti-integrin mAb)

Colorectal cancer

Phase II

DI17E6 (Anti-integrin mAb)

Prostate cancer

Phase II

Pimasertib (MEK inhibitor)

Pancreatic cancer

Phase II

Pimasertib (MEK inhibitor)

Cutaneous melanoma

Phase II

Pimasertib/PI3K inhibitor combination

Solid tumors

Phase I ¹

C-Met kinase inhibitor

Solid tumors

Phase I

Sym004 (anti-EGRF Ab mixture)

Head and neck cancer

Phase II

Sym004 (anti-EGRF Ab mixture)

Solid tumors

Phase I

MEK inhibitor 2

Solid tumors

Phase I

NHS-IL 12 (cancer immunotherapy)

Solid tumors

Phase I ²

Immunology

Atacicept (anti-Blys/anti-APRIL fusion protein)

Systemic lupus erythematosus

Phase II

Sprifermin (fibroblast growth factor 18)

Cartilage injury repair

Phase II

Sprifermin (fibroblast growth factor 18)

Osteoarthritis

Phase I

Endocrinology

Kuvan® (sapropterin dihydrochloride)

PKU in pediatric patients < 4 years

Phase III³